Monrovia, CA, March 14, 2013 --(PR.com
)-- G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for more than 45 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He is currently chairman of AliveCor, and serves on the boards of directors of Catalyst Biosciences, Depomed, NewBridge Pharmaceuticals, Novadaq Technologies, Targacept, and XDx. Previously he served as chairman of the boards of BioImagene, Abunda Nutrition, and Pharmasset. He has received the Richard Bolte, Sr. Award for Supporting Industries from the Chemical Heritage Foundation, a Lifetime Achievement Award from Scrip, the BayBio Pantheon DiNA Lifetime Achievement Award for his biotech leadership worldwide, and the Alan Cranston Living Legend Award for advancing biomedical research globally. In 2002, he was recognized as a biotech investment visionary by Scientific American magazine.
Diabetes Summit 2013 brings together venture capitalists, industry experts and leaders from academic institutions to cover many current and relevant aspects of diabetes. The following companies will be represented Rhythm, NIH, Novo Nordisk, Johnson and Johnson, Astra Zeneca, Thermo Fisher, Merck, Mesoblast, Zafgen, Medpace, Mannkind, Metanomics, Boston University, Harvard, Arizona State, Tufts, etc.
GTC’s Diabetes Summit 2013 will run concurrently on April 29-30 in Boston, MA with Stem Cell Summit 2013. These two Summits will provide delegates unmatched learning and networking opportunities in the following tracks, provided through our Summit Pass:
1) Stem Cell Research and Regenerative Medicine
4) Stem Cell Commercialization and Partnering
3) 6th Diabetes Drug Discovery
4) 3rd Diabetes Partnering and Deal-making
For more information, please visit www.gtcbio.com/diabetes